Conference Coverage
Conference Coverage
Prognostic factors guide mantle cell treatment decisions
CHICAGO –
Conference Coverage
CAR T-cell studies dominate ongoing cellular therapy trials
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
Conference Coverage
Ibrutinib/venetoclax shows early promise in relapsed CLL
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy...
Conference Coverage
Rapid venetoclax dose escalation aids relapsed CLL
STOCKHOLM – A hospital-based dose-escalation protocol got CLL patients up to the target dose of venetoclax in 12 days, versus 35 days with the...
Conference Coverage
‘Very encouraging’ results in BPDCN
STOCKHOLM—Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell...
Conference Coverage
Doc reports favorable results from trial on hold
STOCKHOLM—Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory...
Conference Coverage
CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort
CHICAGO – Could liso-cel be the next CAR T-cell therapy to compete in DLBCL?
Conference Coverage
Inhibitor exhibits activity in B- and T-cell NHLs
STOCKHOLM—The dual SYK/JAK inhibitor cerdulatinib has demonstrated efficacy in a phase 2 trial of patients with heavily pretreated B- and T-cell...
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.